<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742518</url>
  </required_header>
  <id_info>
    <org_study_id>SM04554-AGA-05</org_study_id>
    <nct_id>NCT03742518</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia</brief_title>
  <official_title>Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% &amp; 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samumed LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samumed LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey,
      will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied
      daily to the scalp of male androgenetic alopecia (AGA) subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute non-vellus hair count in target area</measure>
    <time_frame>Week 48</time_frame>
    <description>Absolute non-vellus hair count in target area by phototrichogram (PTG) analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute non-vellus hair count in target area</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Absolute non-vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute vellus hair count in target area</measure>
    <time_frame>Weeks 12, 24, 36 and 48</time_frame>
    <description>Absolute vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute total hair count in target area</measure>
    <time_frame>Weeks 12, 24, 36 and 48</time_frame>
    <description>Absolute total hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non-vellus hair count in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in non-vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vellus hair count in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in vellus hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total hair count in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in total hair count in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average non-vellus hair shaft thickness in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in average non-vellus hair shaft thickness in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average non-vellus hair density in target area</measure>
    <time_frame>Baseline, and Weeks 12, 24, 36 and 48</time_frame>
    <description>Change from baseline in average non-vellus hair density (cumulative non-vellus hair shaft thickness) in target area by PTG analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of hair growth</measure>
    <time_frame>Weeks 6, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Subjects will complete a questionnaire for hair growth while referencing the global scalp photograph taken at the visit as compared to their baseline global scalp photograph. The scale for the questionnaire ranges from -3 to +3 (-3 indicates the worst outcome and +3 indicates the best outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subject assessment of hair satisfaction</measure>
    <time_frame>Baseline, and Weeks 6, 12, 18, 24, 30, 36, 42 and 48</time_frame>
    <description>Subjects will complete a questionnaire for hair satisfaction while referencing the global scalp photograph taken at the visit as compared to their baseline global scalp photograph. The scale for the questionnaire ranges from -3 to +3 (-3 indicates the worst outcome and +3 indicates the best outcome).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">625</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Topical SM04554 0.15% solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.15% solution, once daily for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical SM04554 0.25% solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.25% solution, once daily for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical vehicle solution, once daily for up to 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical SM04554 solution</intervention_name>
    <description>Study medication application will be performed by the individual subject at approximately the same time each day.</description>
    <arm_group_label>Topical SM04554 0.15% solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical SM04554 solution</intervention_name>
    <description>Study medication application will be performed by the individual subject at approximately the same time each day.</description>
    <arm_group_label>Topical SM04554 0.25% solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical vehicle solution</intervention_name>
    <description>Vehicle solution application will be performed by the individual subject at approximately the same time each day.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being a Turkish citizen

          -  Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 3V or 4

          -  Willing to inform females, with whom they may interact, that they are using a topical
             investigational product and direct contact should be avoided as potential harm to a
             fetus is unknown

          -  Willing and able to attend all study visits

          -  Willing to maintain the same hair style and length as at the study start for the
             duration of the study

          -  Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers)
             for the duration of the study; daily styling products (e.g., hair gel, mousse, styling
             spray) will be allowed on non-study visit days

          -  Willing to use mild non-medicated shampoo and conditioner for the duration of the
             study

          -  Able to read and understand Turkish

          -  Ability to comprehend and willing to sign an informed consent form

        Exclusion Criteria:

          -  Males who are sexually active, and have a partner who is capable of becoming pregnant,
             if neither has had surgery to become sterilized, and/or who are not willing to use
             condom or whose partner is not using a highly effective method of birth control that
             includes double barrier, intrauterine device, or hormonal contraceptive combined with
             single barrier, or abstinence during the study treatment period until 90 days post
             last dose of study medication

          -  Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia

          -  Scalp hair loss on the treatment area, due to disease, injury, or medical therapy

          -  History of surgical correction (e.g., hair transplantation, scalp reduction) of hair
             loss on the scalp

          -  Previous exposure to SM04554

          -  Use of any products (e.g., finasteride, minoxidil, platelet rich plasma, biotin) or
             devices (e.g., laser light therapy) purported to promote scalp hair growth within 24
             weeks prior to the start of the study

          -  Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone
             acetate, cimetidine) within 12 weeks prior to the start of the study

          -  Use of medications that potentially cause drug-induced hair loss (e.g.,
             depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone,
             testosterone, divalproex sodium) within 12 weeks prior to the start of the study

          -  Current use of an occlusive wig, hair extensions, or hair weaves

          -  History of hypersensitivity or allergies to any ingredient of the study medication

          -  Participation in any other investigational drug or medical device trial, which
             includes or included administration of an investigational study medication or medical
             device, within 30 days or 5 half-lives of the investigational agent, whichever is
             longer, prior to the start of the study

          -  Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30
             days prior to the start of the study

          -  Use of medicated shampoo or conditioner (medicated shampoo and conditioner refers to
             any prescription shampoo or conditioner as well as any over-the-counter medicated
             shampoo or conditioner, such as those for treatment of dandruff or promoting hair
             growth) within 30 days prior to the start of the study

          -  Subjects who are immediate family members (spouse, parent, child, or sibling;
             biological or legally adopted) of personnel directly affiliated with the study at the
             investigative site, or are directly affiliated with the study at the investigative
             site

          -  Subjects employed by Samumed, LLC or Samumed Turkey, or any of its affiliates or
             development partners (i.e., an employee, temporary contract worker, or designee)
             responsible for the conduct of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Samumed LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06680</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denizli</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ä°zmir</city>
        <zip>35180</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male pattern baldness</keyword>
  <keyword>SM04554</keyword>
  <keyword>AGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

